Drug Patent List
Litigation OpportunitiesNew
Newsletter
Weekly Digest

Pharsight

Eagle Pharms Drug Patent Portfolio

Eagle Pharms owns 4 orange book drugs protected by 27 US patents Given below is the list of Eagle Pharms's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11793813 Pemetrexed formulations 19 Feb, 2036
Active
US9604990 Crystalline forms of pemetrexed diacid and manufacturing processes therefor 28 Oct, 2035
Active
US10052385 Formulations of bendamustine 15 Mar, 2033
Active
US9000021 Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration 15 Mar, 2033
Active
US9034908 Formulations of bendamustine 15 Mar, 2033
Active
US9144568 Formulations of bendamustine 15 Mar, 2033
Active
US9572887 Formulations of bendamustine 15 Mar, 2033
Active
US9579384 Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration 15 Mar, 2033
Active
US9597397 Formulations of bendamustine 15 Mar, 2033
Active
US9597398 Formulations of bendamustine 15 Mar, 2033
Active
US9597399 Formulations of bendamustine 15 Mar, 2033
Active
US8609707 Formulations of bendamustine 11 Aug, 2031
Active
US10010533 Formulations of bendamustine 28 Jan, 2031
Active
US11103483 Formulations of bendamustine 28 Jan, 2031
Active
US11844783 Formulations of bendamustine 28 Jan, 2031
Active
US11872214 Formulations of Bendamustine 28 Jan, 2031
Active
US9265831 Formulations of bendamustine 28 Jan, 2031
Active
US9572796 Formulations of bendamustine 28 Jan, 2031
Active
US9572797 Formulations of bendamustine 28 Jan, 2031
Active
US8791270 Bendamustine pharmaceutical compositions 12 Jul, 2026
Active
US8791270 Bendamustine pharmaceutical compositions 12 Jan, 2026
Active
US7758890 Treatment using dantrolene 30 Jun, 2025
Active
US8685460 Treatment using dantrolene 15 Feb, 2023 Expired
US8110225 Treatment using dantrolene 24 Dec, 2022 Expired
US8604072 Treatment using dantrolene 20 Jul, 2022 Expired
US9884044 Treatment using dantrolene 13 Jun, 2022 Expired
US7772209 Antifolate combination therapies 24 May, 2022 Expired


Given below is the list of recent legal activities going on the following drug patents of Eagle Pharms.

Activity Date Patent Number
Patent litigations
Expire Patent
Critical
11 Mar, 2024 US8110225
Patent eGrant Notification 16 Jan, 2024 US11872214
Email Notification
Critical
16 Jan, 2024 US11872214
Recordation of Patent eGrant 16 Jan, 2024 US11872214
Recordation of Patent Grant Mailed
Critical
16 Jan, 2024 US11872214
Patent Issue Date Used in PTA Calculation
Critical
16 Jan, 2024 US11872214
Email Notification
Critical
16 Jan, 2024 US11872214
Recordation of Patent Grant Mailed
Critical
16 Jan, 2024 US11872214
Recordation of Patent eGrant 16 Jan, 2024 US11872214
Patent eGrant Notification 16 Jan, 2024 US11872214
Patent Issue Date Used in PTA Calculation
Critical
16 Jan, 2024 US11872214
Mail Patent eGrant Notification 16 Jan, 2024 US11872214
Mail Patent eGrant Notification 16 Jan, 2024 US11872214
Email Notification
Critical
28 Dec, 2023 US11872214
Email Notification
Critical
28 Dec, 2023 US11872214


Eagle Pharms's Drug Patent Litigations

Eagle Pharms's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Jun 14, 2013, against patent number US7772209. The petitioner Accord Healthcare, Inc., USA, challenged the validity of this patent, with Eli Lilly and Company as the respondent. Click below to track the latest information on how companies are challenging Eagle Pharms's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US7772209 November, 2015 FWD Entered
(05 Oct, 2017)
Eli Lilly and Company Neptune Generics, LLC
US7772209 December, 2015 FWD Entered
(05 Oct, 2017)
Eli Lilly and Company Sandoz Inc.
US7772209 June, 2016 FWD Entered
(05 Oct, 2017)
Eli Lilly and Company Wockhardt Bio AG
US7772209 July, 2016 FWD Entered
(05 Oct, 2017)
Eli Lilly and Company Apotex Inc.
US7772209 July, 2016 FWD Entered
(05 Oct, 2017)
Eli Lilly and Company Teva Pharmaceuticals USA, Inc.
US7772209 July, 2016 FWD Entered
(05 Oct, 2017)
Eli Lilly and Company Wockhardt Bio AG
US7772209 July, 2016 FWD Entered
(05 Oct, 2017)
Eli Lilly and Company Apotex Inc.
US8791270 October, 2015 Terminated-Settled
(25 Aug, 2016)
Cephalon, Inc. Fresenius Kabi USA, LLC
US8791270 October, 2015 Terminated-Denied
(13 Apr, 2016)
Cephalon, Inc. AGILA SPECIALTIES INC.
US7772209 June, 2013 Terminated-Denied
(01 Oct, 2013)
Eli Lilly and Company Accord Healthcare, Inc., USA


Eagle Pharms Drug Patents' Oppositions Filed in EPO

Eagle Pharms drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 17, 2008, by Teva Pharmaceutical Industries Ltd.. This opposition was filed on patent number EP01948214A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP11737745A Jul, 2017 FRKelly Patent maintained as amended
EP11737745A Jul, 2017 Wittkopp, Alexander Patent maintained as amended
EP11737745A Jul, 2017 Fresenius Kabi Deutschland GmbH Patent maintained as amended
EP11737745A Jul, 2017 isarpatent - Patent- und Rechtsanwälte Behnisch Barth Charles Hassa Peckmann und Partner mbB Patent maintained as amended
EP06718390A Jan, 2014 Accord Healthcare Revoked
EP06718390A Jan, 2014 Taylor Wessing LLP Revoked
EP06718390A Jan, 2014 Gallafent, Alison Revoked
EP06718390A Jan, 2014 Bendalis GmbH Revoked
EP06718390A Dec, 2013 Actavis Group PTC ehf Revoked
EP06718390A Dec, 2013 LEK Pharmaceuticals d.d. Revoked
EP06718390A Dec, 2013 Helm AG Revoked
EP01948214A Oct, 2012 Actavis Deutschland GmbH & Co. KG Opposition rejected
EP01948214A Jan, 2008 Teva Pharmaceutical Industries Ltd. Opposition rejected


Eagle Pharms's Family Patents

Eagle Pharms drugs have patent protection in a total of 34 countries. It's US patent count contributes only to 40.9% of its total global patent coverage. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Eagle Pharms Drug List

Given below is the complete list of Eagle Pharms's drugs and the patents protecting them.


1. Belrapzo

Belrapzo is protected by 9 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8609707 Formulations of bendamustine 11 Aug, 2031
(6 years from now)
Active
US10010533 Formulations of bendamustine 28 Jan, 2031
(6 years from now)
Active
US11103483 Formulations of bendamustine 28 Jan, 2031
(6 years from now)
Active
US11844783 Formulations of bendamustine 28 Jan, 2031
(6 years from now)
Active
US11872214 Formulations of Bendamustine 28 Jan, 2031
(6 years from now)
Active
US9265831 Formulations of bendamustine 28 Jan, 2031
(6 years from now)
Active
US9572796 Formulations of bendamustine 28 Jan, 2031
(6 years from now)
Active
US9572797 Formulations of bendamustine 28 Jan, 2031
(6 years from now)
Active
US8791270 Bendamustine pharmaceutical compositions 12 Jan, 2026
(1 year, 2 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Belrapzo's drug page


2. Bendeka

Bendeka is protected by 19 patents, out of which none have expired yet. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US10052385 Formulations of bendamustine 15 Mar, 2033
(8 years from now)
Active
US9000021 Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration 15 Mar, 2033
(8 years from now)
Active
US9034908 Formulations of bendamustine 15 Mar, 2033
(8 years from now)
Active
US9144568 Formulations of bendamustine 15 Mar, 2033
(8 years from now)
Active
US9572887 Formulations of bendamustine 15 Mar, 2033
(8 years from now)
Active
US9579384 Method of treating bendamustine-responsive conditions in patients requiring reduced volumes for administration 15 Mar, 2033
(8 years from now)
Active
US9597397 Formulations of bendamustine 15 Mar, 2033
(8 years from now)
Active
US9597398 Formulations of bendamustine 15 Mar, 2033
(8 years from now)
Active
US9597399 Formulations of bendamustine 15 Mar, 2033
(8 years from now)
Active
US8609707 Formulations of bendamustine 11 Aug, 2031
(6 years from now)
Active
US10010533 Formulations of bendamustine 28 Jan, 2031
(6 years from now)
Active
US11103483 Formulations of bendamustine 28 Jan, 2031
(6 years from now)
Active
US11844783 Formulations of bendamustine 28 Jan, 2031
(6 years from now)
Active
US11872214 Formulations of Bendamustine 28 Jan, 2031
(6 years from now)
Active
US9265831 Formulations of bendamustine 28 Jan, 2031
(6 years from now)
Active
US9572796 Formulations of bendamustine 28 Jan, 2031
(6 years from now)
Active
US9572797 Formulations of bendamustine 28 Jan, 2031
(6 years from now)
Active
US8791270
(Pediatric)
Bendamustine pharmaceutical compositions 12 Jul, 2026
(1 year, 8 months from now)
Active
US8791270 Bendamustine pharmaceutical compositions 12 Jan, 2026
(1 year, 2 months from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Bendeka's drug page


3. Pemfexy

Pemfexy is protected by 3 patents, out of which 1 has expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US11793813 Pemetrexed formulations 19 Feb, 2036
(11 years from now)
Active
US9604990 Crystalline forms of pemetrexed diacid and manufacturing processes therefor 28 Oct, 2035
(11 years from now)
Active
US7772209 Antifolate combination therapies 24 May, 2022
(2 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Pemfexy's drug page


4. Ryanodex

Ryanodex is protected by 5 patents, out of which 4 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7758890 Treatment using dantrolene 30 Jun, 2025
(8 months from now)
Active
US8685460 Treatment using dantrolene 15 Feb, 2023
(1 year, 8 months ago)
Expired
US8110225 Treatment using dantrolene 24 Dec, 2022
(1 year, 9 months ago)
Expired
US8604072 Treatment using dantrolene 20 Jul, 2022
(2 years ago)
Expired
US9884044 Treatment using dantrolene 13 Jun, 2022
(2 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Ryanodex's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List